Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25114046 | 0.80 | PDE4D (0.45) | PDE4DIRAK4IRAK1KCNH2PDE4B | |
| SCHEMBL26762028 | 0.78 | PDE4D (0.43) | PDE4DIRAK4IRAK1KCNH2PDE4B | |
| SCHEMBL25113904 | 0.78 | PDE4D (0.43) | PDE4DIRAK4IRAK1KCNH2PDE4B | |
| SCHEMBL25113851 | 0.76 | PDE4D (0.46) | PDE4DIRAK4IRAK1KCNH2PDE4B | |
| SCHEMBL26831046 | 0.75 | IRAK4 (0.46) | PDE4DIRAK4IRAK1KCNH2 | |
| SCHEMBL25114616 | 0.71 | IRAK4 (0.43) | PDE4DIRAK4IRAK1KCNH2 | |
| SCHEMBL29751483 | 0.70 | IRAK4 (0.42) | PDE4DIRAK4IRAK1KCNH2 | |
| SCHEMBL24608088 | 0.70 | IRAK4 (0.42) | PDE4DIRAK4IRAK1KCNH2 | |
| SCHEMBL24345431 | 0.69 | FPR2 (0.34) | — | |
| SCHEMBL24447954 | 0.68 | PDE4D (0.36) | PDE4DIRAK4IRAK1KCNH2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | PDE4D 1685/4885IRAK4 2872/4885IRAK1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.